With the significant global obesity epidemic and emerging strong scientific evidence that connected gut microbiota to obesity, intervening obesity by targeting gut microbiota has become a trendy strategy. Particularly the application of probiotics has become remarkably popular because of their expected association with gut microbiota modulation. Although there are many literatures on the effects of probiotics in obese animal models, most of them reported the effects of probiotic bacteria on metabolic indications with limited information on anti-obesity itself. Besides, some probiotics have been shown to reduce certain metabolic symptoms but they failed to achieve weight loss. This report reviewed the current literatures on the anti-obesity effects of next-generation probiotics in various animal obesity models and discussed the beneficial potential of fecal microbiota transplantation in treating obesity in humans. The purpose of this article is to help guide further research improve the probiotic bacteria experiments in more precise animal obesity models by standardizing the anti-obesogenesis, obesity control, and treatment assays and hopefully the evidence-based investigations on harnessing gut microbiota through next-generation probiotics or fecal microbiota transplantation will develop new interventions to promote and achieve anti-obesity.
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| INTRODUCTION
An escalating epidemic of overweight and obesity is now a critical challenge worldwide. Obesity is a complex condition and the cause of obesity is typically associated with the interaction of genetics and environments. Some studies have shown that the genetic variations in FTO region have strong genetic association with polygenetic obesity in human. [1] [2] [3] [4] Yet some genetic association studies suggested that genetic predisposition has a relatively small effect on obesity development when compared to environmental factors, such as dietary lifestyle and physical activity. 5, 6 Recent evidence has demonstrated that gut microbiota alters host metabolism by affecting energy flux and metabolic inflammation associated with obesity and its related health issues. [7] [8] [9] [10] Similar to the cause of obesity, recent studies suggest that environmental factors play a dominant role over genetics in regulating gut microbiome composition. 11 This implicates that gut microbiota might be a key linker between genetic predisposition and environment in obesity. In a mouse diet-induced obesity (DIO) model, germfree mice showed dramatic obesity-resistance. 12 When germ-free mice were transplanted with fecal/gut microbiota from ob/ob mice or obese human individuals, these mice phenocopied the obese phenotype via the microbiota transfer. 13, 14 In contrast to obesogenic gut microbiota, some studies also suggest that the inoculation of leanness-associated gut microbiota can protect mice against obesity both on a healthy diet or a high-fat diet. 14, 15 Recently, accumulating evidences indicated microbiome-based therapies as potential treatments of a variety of diseases. However, the impact of host genetics on microbiome therapeutics remains unclear.
| ANTI-OBESITY: ANTI-OBESOGENESIS, OBESITY CONTROL, AND TREATMENT
Anti-obesity is a term with broad and mixed concept including prevention, control, and treatment of obesity. Anti-obesogenesis is the prevention of obesity and in addition to cosmetic reasons, public awareness of the link between obesity and diseases makes this popular even in nonobese people. Furthermore, obesity control and treatment are some interventions to achieve a significant difference in weight gain/loss in over-weight or obese people. All these three aspects of anti-obesity have tremendous important applications and could be explored and examined in different experimental models.
Behavioral modifications including improving dietary pattern and increasing physical activity are usually considered as ideal strategies to fight against obesity in all these three aspects although studies suggest that exercise alone only has minor effects on weight loss. [16] [17] [18] However, in humans these strategies usually do not last long due to lack of discipline and reduced weight often rebounds. The use of weight-loss drugs is getting popular but they play a minor role due to side effects. Weight loss surgery such as bariatric surgery is probably the most efficient way to achieve obesity treatment but some potential complications make this only applicable in seriously obese patients. Obesity is a natural outcome in our current obesogenic modernization environment of increased availability of inexpensive, energy-dense, and appetizing processed foods and decreased need for physical activity in work and transportation. There is a critical need to develop novel and safe strategies for anti-obesity. Since gut microbiota plays profound and critical roles in nutrients/energy supply/immune system homeostasis in obesity, 19 here we review multiple studies researching anti-obesity options through modulating gut microbiota.
3 | MICROBIOME-BASED ANTI-OBESITY POTENTIAL: NEXT-GENERATION PROBIOTICS AND FECAL MICROBIOTA TRANSPLANTATION 3.1 | The history and the definition of the word "probiotics"
With the increase of articles and merchandises using the word "probiotics," the misunderstanding and controversy may occur due to unequal or imprecise definition of probiotics, which confuse not only the investigators but also manufacturers and consumers. In Etymology, the term "probiotics" is a compound word, which composes of the Latin preposition "pro" (means "for") and the Greek noun "bios"
(means "life") or adjective "biotics" (means "fit for life"). 20, 21 This word appeared for the first time in an article by F. Vergin in 1954 to describe some gut bacteria beneficial to the host human. 22 This word was also used by D.M. Lilly and R.H. Stillwell in 1965. However, in their article, the probiotics was designated to express some growthpromoting substances, not the microbes, produced from the protozoa. 23 In 1974, this word was still used ambiguously and it may include both organism and their substances. 24 In 1989, R. Fuller specifically defined the probiotics as "a live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance," to point out that the live cells is a necessary condition for description of probiotics. 24 
| Discovery of the next-generation probiotics
The use of probiotics has a long history that could be traced back as early as 3000 B.C. However, their economic importance is just uncovered in last two decades. In the marketplace, the most commonly used probiotics are lactic acid bacteria, primarily include Lactobacullus spp.
and Bifidobacterium spp., whereas Bacillus spp., Clostridium butyricum, Escherichia coli, Enterococcus, Weissella spp., and yeast Saccharomyces spp. are relatively rare in use. 26 These microbes, with long history in use and sufficient evidences for safety assurance, are generally classified into the traditional probiotics. However, these probiotics are just a small portion of entire microbial community, and there are still a lot of microbes with probiotic potential to be discovered. The breakthrough of molecular biology techniques, particularly the development of next-generation sequencing techniques, largely improves the classification and characterization of microbes, which in turn, accelerates the discovery of new probiotics. 27, 28 The high-throughput, high-resolution, and low-cost properties of new DNA and RNA sequencing approaches provide the opportunity for investigators to study the microbial diversity broadly and to mine the microbial genome deeply.
Nowadays, the study of microbiome has become a flourishing research field, and the rate of microbiome-related publications has significantly escalated. By analyzing the microbiome between healthy and diseased individuals, a variety of bacteria have been found to correlate with diseases. 29, 30 Meanwhile, some bacteria were found being more abundant in the healthy population and might have potential to be used as probiotics. [31] [32] [33] [34] These newly discovered bacteria, originated from the microbiome-based analysis, could be referred to as the "next-generation probiotics." Indeed, the amelioration of culture system, including the development of bioreactors, [34] [35] [36] formulation of new isolation protocol, 33 and modification of culture media, 37,38 also contribute to the discovery of next-generation probiotics. The development of metabolomics, an advanced technique for analyzing both the composition of metabolites from microbes and host, allows the researchers to establish the potential link between microbes and host, and provides the possible mechanisms for further investigation. 34, 39 All these improvements enable the researchers to select the nextgeneration probiotics more efficiently, either from the traditional sources such as intestinal content and dairy food or from the unconventional sources such as fermented foods, grain, vegetables, fruit, honey-comb, and soil. 38 Moreover, the genetically modified microorganisms may also be included in the next-generation probiotics, despite their use still has ethical concerns and the safety problem needs to be solved. 26, 40 Together, the next-generation probiotics, which have no history of use, can be discovered by novel molecular biology approaches or created by gene editing ( Figure. 2). However, it is notable that the term "next-generation probiotics" is relative and contemporary. The newly discovered probiotics may no longer belong to the next-generation probiotics if the evidence is sufficient to allow them be included in the current probiotics or be used as drug, in which they would be called "live biotherapeutic products." and its associated disorders in rodents. 31 By DIO experimental model, 49 and L. plantarum Ln4. 50 According to the FAO/WHO definition of probiotics, we summarized the information of the newly discovered anti-obesity probiotics in Table 1 , especially in the aspect of their experimental models and anti-obesity effects, to examine: (a) the adequate amounts; (b) the
The historical perspective of the definition of probiotics administration conditions; (c) the ability to colonize or survive in the gut; and (d) the anti-obesity effects of these microbes.
In addition to Lactobacillus spp. and Bifidobacterium spp., a variety of bacteria have also been recognized as anti-obesity probiotics.
Administration of Pediococcus pentosaceus LP28, a lactic acid bacterium isolated from longan fruit, showed the partial suppression of high-fat diet-induced body weight gain. 51 The Bacteroides uniformis CECT 7771 isolated from the stools of a healthy breast-fed infant was also reported to partially decrease the body weight gain in DIO mice. 52 Although the administration of B. uniformis CECT 7771 did not reduce the epididymal fat mass in DIO mice, the decreased levels of lipid in the liver and blood and the improvement of insulin tolerance were observed. Recently, a newly discovered bacterium named Akkermansia muciniphila has been thoroughly studied on its probiotic poten- A. muciniphila abundance was inversely correlated with the body weight gain in pregnant women. 54 Another study by Karlsson et al. showed that the A. muciniphila was significantly lower in the obese/overweight children 55 and similarly, the abundance of A. muciniphila was reduced in ob/ob and DIO mice. or pasteurized P. goldsteinii, suggesting that the live P. goldsteinii is still required. Together, the current studies have established a set of methods to examine a new anti-obesity probiotic, in compliance with the FAO/WHO definition of probiotics.
| The blind spots, limitations, and challenges
While the rules and methods for defining probiotics have been established, there are potential blind spots resulted from the methodological limitations, which might cast a shadow on the use of probiotics.
One challenge is that the colonization of probiotics on the intestinal epithelium is still difficult to examine in vivo. While the adhesion assay can be performed by in vitro models that using Caco-2 or HT29 epithelial cells to mimic gut epithelium, it is still not equal to the environ- (Table 1) , and therefore the description of "live microorganism" is one of the blind spots of FAO/WHO definition.
Another challenge is that the optimal amount of probiotics administration is still not clear. While a numerous of experimental models have been used, the divergence in administrating conditions, such as the differences in resuspension solution, obese models and the host animals may lead to diverse results and conclusions. For example, while the PBS or normal saline were generally used for dilution of probiotics, some studies used the skim milk for resuspension 52 or generation of fermented milk 41, 46 (Table 1) . It is required to test whether the anti-obesity outcome is resulted from the probiotics' nature or other beneficial components, such as the metabolites of probiotics or the materials of resuspension solution. In addition, DIO is an obese model that is generally used for examining the anti-obesity effect of probiotics, but it can be divided into prefeeding or cofeeding models according to the intervention time point of probiotics. Prefeeding the animals with high-fat diet can induce a certain level of obesity before administrating probiotics; however, this may counteract the antiobesity impacts of probiotics, and it is hard to go back to the normal weight gain in comparison with nonobesity animals. P. pentosaceus LP28, 51 L. casei Shirota, 42 L. rhamnosus PB01 (DSM 14870), 43 and L. sakei OK67 44 were examined under a prefeeding DIO model, but it should be noted that their anti-obesity effects might be underestimated. Notably, although the anti-obesity probiotics were mostly examined in the rodent models, it should be finally tested through the clinical trials in human. Moreover, the side effects of probiotics or gender effects of host remains sporadic in studies of anti-obesity probiotics, and these should be thoroughly examined prior to the marketing. To obtain the "adequate amounts" of probiotics for administration, further studies to validate the benefits and minimize the side effects in human would be required. 60 Recently, some metagenome-wide association studies (MGWAS) showed that the variations in human genome are associated with certain microbiome signature. 61, 62 The human enterotypes are determined by gut microbiota composition 63, 64 and have been suggested to be associated with response to diet. 65 The taxonomic composition, richness, diversity and temporal stability may contribute to distinct functional properties in different enterotypes. 66 Human gut microbiome is highly influenced by diet and other environmental factors, but some studies found specific taxa and ecological metrics in a gut microbiota are heritable. [67] [68] [69] The heritable archaeon
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| THE INTERACTION OF HOST'S GENETICS AND GUT MICROBIOME IN OBESITY-RESISTANCE
Methanobrevibacter smithii and bacteria genus Blautia were observed to be associated with higher body mass index and higher visceral fat, respectively. 70, 71 In contrast, the heritable family Christensenellaceae are negatively correlated with obesity. 67 The family Christensenellaceae is the most heritable taxon in human 77 or dual specificity phosphatase 6 (Dusp6) deficiency. 15 Currently, gut microbiomes are usually analyzed by performing 16S rRNA gene sequencing or metagenome sequencing on fecal samples. 78 Although these kinds of data can provide basic information of microbial taxa and ecological metrics, the dynamic variation of a microbiome and the gene-microbiota interaction will be difficult to address by these approaches. The microbiome data of a fecal sample comes from a mixture of mucosal and luminal contents from different gut regions. To investigate the microbiota composition on mucosal surface or perform a prospective study may help further elucidate the roles of host genetics in colonization, diversity and stability of microbiomes in gut. 61, 79 Whether host genetics will affect the effectiveness of probiotics supplement, microbiota-replacement, and FMT should be carefully considered and studied.
| CONCLUSIONS
Because of the significant global obesity epidemic, there are many published reports on the tests of probiotics in obese animal models. However, majority of them reported the effects on metabolic symptoms such as hyperlipidemia or hyperglycemia but the information on antiobesity itself is rather sparse. Some probiotics have been shown to reduce certain metabolic symptoms but they failed to achieve weight loss. Since obesity is a risk factor associated with many more diseases besides metabolic disorders, the anti-obesity alone is indeed important.
Although diet and exercise might remain the cornerstones on fighting obesity, the utilization of some recent microbiome-based strategies has abundant potential for those who do not keep health routine or even to boost the beneficial effects of behavior modifications. Overall in this review some next-generation probiotics or FMT have been discussed precisely on anti-obesity. Improving the animal obesity models by standardizing the anti-obesogenesis, obesity control and treatment experiments would enhance their commercial or clinical potential, and the anti-obesity claims made needs to be further validated and firmly established by properly designed clinical trials. Hopefully the investigations on altering gut microbiota through next-generation probiotics or FMT will provide new therapeutic avenues against obesity.
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